216 related articles for article (PubMed ID: 27226489)
1. Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells.
Velmurugan R; Challa DK; Ram S; Ober RJ; Ward ES
Mol Cancer Ther; 2016 Aug; 15(8):1879-89. PubMed ID: 27226489
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
3. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.
Shi Y; Fan X; Deng H; Brezski RJ; Rycyzyn M; Jordan RE; Strohl WR; Zou Q; Zhang N; An Z
J Immunol; 2015 May; 194(9):4379-86. PubMed ID: 25795760
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
6. Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice.
Boross P; Jansen JH; Pastula A; van der Poel CE; Leusen JH
Immunol Lett; 2012 Mar; 143(1):44-52. PubMed ID: 22285696
[TBL] [Abstract][Full Text] [Related]
7. Tight nanoscale clustering of Fcγ receptors using DNA origami promotes phagocytosis.
Kern N; Dong R; Douglas SM; Vale RD; Morrissey MA
Elife; 2021 Jun; 10():. PubMed ID: 34080973
[TBL] [Abstract][Full Text] [Related]
8. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
9. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro.
Leidi M; Gotti E; Bologna L; Miranda E; Rimoldi M; Sica A; Roncalli M; Palumbo GA; Introna M; Golay J
J Immunol; 2009 Apr; 182(7):4415-22. PubMed ID: 19299742
[TBL] [Abstract][Full Text] [Related]
10. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
11. Phagocytosis of antibody-opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages.
Velmurugan R; Ramakrishnan S; Kim M; Ober RJ; Ward ES
Traffic; 2018 Apr; 19(4):273-284. PubMed ID: 29437282
[TBL] [Abstract][Full Text] [Related]
12. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells.
Richards JO; Karki S; Lazar GA; Chen H; Dang W; Desjarlais JR
Mol Cancer Ther; 2008 Aug; 7(8):2517-27. PubMed ID: 18723496
[TBL] [Abstract][Full Text] [Related]
13. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection.
Yamada DH; Elsaesser H; Lux A; Timmerman JM; Morrison SL; de la Torre JC; Nimmerjahn F; Brooks DG
Immunity; 2015 Feb; 42(2):379-390. PubMed ID: 25680277
[TBL] [Abstract][Full Text] [Related]
14. Enzymatic Inactivation of Endogenous IgG by IdeS Enhances Therapeutic Antibody Efficacy.
Järnum S; Runström A; Bockermann R; Winstedt L; Crispin M; Kjellman C
Mol Cancer Ther; 2017 Sep; 16(9):1887-1897. PubMed ID: 28533435
[TBL] [Abstract][Full Text] [Related]
15. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
Lu Y; Vernes JM; Chiang N; Ou Q; Ding J; Adams C; Hong K; Truong BT; Ng D; Shen A; Nakamura G; Gong Q; Presta LG; Beresini M; Kelley B; Lowman H; Wong WL; Meng YG
J Immunol Methods; 2011 Feb; 365(1-2):132-41. PubMed ID: 21185301
[TBL] [Abstract][Full Text] [Related]
16. Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Dahal LN; Huang CY; Stopforth RJ; Mead A; Chan K; Bowater JX; Taylor MC; Narang P; Chan HTC; Kim JH; Vaughan AT; Forconi F; Beers SA
J Immunol; 2018 Aug; 201(4):1211-1221. PubMed ID: 29997125
[TBL] [Abstract][Full Text] [Related]
17. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
18. CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor- and Complement Receptor 3-Dependent Mechanisms.
Amash A; Wang L; Wang Y; Bhakta V; Fairn GD; Hou M; Peng J; Sheffield WP; Lazarus AH
J Immunol; 2016 Apr; 196(8):3331-40. PubMed ID: 26944929
[TBL] [Abstract][Full Text] [Related]
19. Macrophages are critical effectors of antibody therapies for cancer.
Weiskopf K; Weissman IL
MAbs; 2015; 7(2):303-10. PubMed ID: 25667985
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Su S; Zhao J; Xing Y; Zhang X; Liu J; Ouyang Q; Chen J; Su F; Liu Q; Song E
Cell; 2018 Oct; 175(2):442-457.e23. PubMed ID: 30290143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
